Intelligent Medicine Acquisition (Intelligent Medicine Acquisition) Equity-to-Asset : 0.95 (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Intelligent Medicine Acquisition Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Intelligent Medicine Acquisition's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $202.40 Mil. Intelligent Medicine Acquisition's Total Assets for the quarter that ended in Dec. 2022 was $214.03 Mil.

The historical rank and industry rank for Intelligent Medicine Acquisition's Equity-to-Asset or its related term are showing as below:

IQMDU' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.9 Med: 0.92 Max: 0.95
Current: 0.95

During the past 2 years, the highest Equity to Asset Ratio of Intelligent Medicine Acquisition was 0.95. The lowest was 0.90. And the median was 0.92.

IQMDU's Equity-to-Asset is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.81 vs IQMDU: 0.95

Intelligent Medicine Acquisition Equity-to-Asset Historical Data

The historical data trend for Intelligent Medicine Acquisition's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Medicine Acquisition Equity-to-Asset Chart

Intelligent Medicine Acquisition Annual Data

Trend

Dec21

Dec22

Equity-to-Asset

0.90

0.95

Intelligent Medicine Acquisition Quarterly Data
	Feb21	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22
Equity-to-Asset	Get a 7-Day Free Trial			-	0.90	0.94	0.94	0.95

Competitive Comparison of Intelligent Medicine Acquisition's Equity-to-Asset

For the Shell Companies subindustry, Intelligent Medicine Acquisition's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intelligent Medicine Acquisition's Equity-to-Asset Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Intelligent Medicine Acquisition's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Intelligent Medicine Acquisition's Equity-to-Asset falls into.

Intelligent Medicine Acquisition Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Intelligent Medicine Acquisition's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	202.399	/	214.034
	=

Intelligent Medicine Acquisition's Equity to Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

Equity to Asset (Q: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	202.399	/	214.034
	=

Intelligent Medicine Acquisition (NAS:IQMDU) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Intelligent Medicine Acquisition Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Intelligent Medicine Acquisition's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelligent Medicine Acquisition (Intelligent Medicine Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Intelligent Medicine Acquisition Corp (NAS:IQMDU) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

9001 Burdette Road, Bethesda, MD, USA, 20817

Website

https://iqmdspac.com

Intelligent Medicine Acquisition Corp is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.

Executives

Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Saba Capital Management, L.p.	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Joseph L Schocken	director	2800 UNION SQUARE, 600 UNIVERSITY STREET, SEATTLE WA 98101
Kavita Patel	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jack Hidary	director	3 PARK AVENUE, NEW YORK NY 10016
Gregory C Simon	director, officer: CEO and CFO	9001 BURDETTE RD., BETHESDA MD 20817
Patience Marime-ball	director	9001 BURDETTE RD., BETHESDA MD 20817
Intelligent Medicine Sponsor Llc	10 percent owner	9001 BURDETTE ROAD, BETHESDA MD 20817

Intelligent Medicine Acquisition (Intelligent Medicine Acquisition) Headlines

From GuruFocus

Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders

By Business Wire Business Wire • 02-03-2023

Intelligent Medicine Acquisition Corp. Announces Closing of Upsized $207,000,000 Initial Public Offering

By Business Wire Business Wire • 11-10-2021

Intelligent Medicine Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing December 27, 2021

By Business Wire Business Wire • 12-23-2021

Intelligent Medicine Acquisition Corp. Announces It Will Redeem Its Public Shares

By Business Wire Business Wire • 04-26-2023